source
- Slate Medicines secures $245M financing and Nasdaq listing via reverse merger with Fulcrum TherapeuticsSlate Medicines, a North Carolina biotech, is moving toward a Nasdaq listing through a reverse merger with Fulcrum Therapeutics, six months after emerging from stealth. The transaction includes a…
- Chinese biotech CEOs say US tensions won’t curb booming licensing dealsChinese biotech CEOs say they are not worried about rising US political tension and regulatory scrutiny. US lawmakers have increased scrutiny, referencing the America First Investment Policy and t…